Examples of successful FY 2018 COAP grant application project narratives:
- Category 1 - Erie County NY Opioid Overdose Outreach Enhancement Program
- Comprehensive Opioid Abuse Site-based Program: Category 6
- Category 2 - Technology-assisted Treatment Projects (Example A)
- Category 2 - Technology-assisted Treatment Projects (Example B)
- Makah Tribe Comprehensive Opioid Abuse Site-Based Program Application
- Category 2 - New York State Unified Court System/Center for Court Innovation/New York State Office of Alcoholism and Substance Abuse Services
- Florida Department of Health Reducing Opioid Abuse and Overdose Deaths in Florida Through Expanded Access to E-FORCSE Data
- Category 6 - Regional Judicial Opioid Initiative Model
FY 2017 Comprehensive Opioid Abuse Site-based Program awards:
- Category 1: Overdose Outreach Projects
- Category 2: Technology-assisted Treatment Projects
- Category 3: System-level Diversion and Alternatives to Incarceration Projects
- Category 4: Statewide Planning, Coordination and Implementation Projects
- Category 5: Harold Rogers Prescription Drug Monitoring Program
- Category 6: Data-driven Responses to Opioid Misuse Projects
COAP TTA cooperative agreement recipients
BJA selected four training and technical assistance providers to provide assistance and a repository of information to states, local jurisdictions, and tribal territories to combat the opioid epidemic.
- Network and Coordination Assistance. The Institute for Intergovernmental Research will provide all of the logistical support for online and in-person training, technical assistance, and publications associated with COAP and PDMPs.
- National Site-based TTA. The Advocates for Human Potential will provide ongoing TTA (both remote and onsite) to site-based grantees throughout the duration of their BJA grant awards. This includes assisting with project design in the planning phase, developing a profile of each grantee that describes the results of the project, facilitating partnerships with relevant stakeholders, overseeing the data collection process, and addressing issues that may hinder a site’s progress in achieving its goals.
- Peer Recovery Support TTA. The Altarum Institute will provide ongoing TTA (both remote and onsite) to all site-based COAP grantees interested in incorporating a peer recovery component into their projects. Altarum will host a symposium on the intersection of recovery support services with criminal justice, child welfare, law enforcement, and emergency departments.
- Prescription Drug Monitoring Programming TTA. Brandeis University will manage the existing online PDMP Resource Center to equip PDMP practitioners with access to a myriad of PDMP resources.
*The COAP TTA collaborative also supports the President’s Commission on Combating Drug Addiction and the Opioid Crisis by informing best practices for addiction prevention and the use and effectiveness of state prescription drug monitoring programs, and by improving access to and availability of treatment services and overdose reversal throughout the country.
Beginning in FY 2002, Congress appropriated funding to the U.S. Department of Justice to support the Prescription Drug Monitoring Program. Prescription monitoring programs help prevent and detect the diversion and abuse of pharmaceutical controlled substances, particularly at the retail level where no other automated information collection system exists. States that have implemented prescription monitoring programs have the capability to collect and analyze prescription data much more efficiently than states without such programs, where the collection of prescription information requires the manual review of pharmacy files, a time-consuming and invasive process.
The purpose of the Prescription Drug Monitoring Program is to enhance the capacity of regulatory and law enforcement agencies to collect and analyze controlled substance prescription data. The program focuses on providing help for states that want to establish a prescription drug monitoring program. Resources are also available to states that wish to expand their existing programs. Program objectives include:
- Building a data collection and analysis system at the state level.
- Enhancing existing programs' ability to analyze and use collected data.
- Facilitating the exchange of collected prescription data among states.
- Assessing the efficiency and effectiveness of the programs funded under this initiative.
The Prescription Drug Monitoring Program was created by the FY 2002 U.S. Department of Justice Appropriations Act (Public Law 107-77).